The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary.

The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn's and Colitis Canada's 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.

Windsor JW ，Kuenzig ME ，Murthy SK ，Bitton A ，Bernstein CN ，Jones JL ，Lee K ，Targownik LE ，Peña-Sánchez JN ，Rohatinsky N ，Ghandeharian S ，Im JHB ，Davis T ，Weinstein J ，Goddard Q ，Benchimol EI ，Kaplan GG ... -  《-》

The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.

Kuenzig ME ，Lee L ，El-Matary W ，Weizman AV ，Benchimol EI ，Kaplan GG ，Nguyen GC ，Bernstein CN ，Bitton A ，Lee K ，Cooke-Lauder J ，Murthy SK ... -  《-》

The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Kuenzig ME ，Benchimol EI ，Lee L ，Targownik LE ，Singh H ，Kaplan GG ，Bernstein CN ，Bitton A ，Nguyen GC ，Lee K ，Cooke-Lauder J ，Murthy SK ... -  《-》

The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs.

People living with inflammatory bowel disease (IBD) and their caregivers are faced with indirect and out-of-pocket costs that they would not otherwise experience. These costs impact one's ability to contribute to the economy to their fullest potential. The indirect costs of IBD in Canada are estimated to be at least $1.51 billion in 2023 and include costs associated with lost productivity resulting from a combination of missed work (absenteeism), decreased workplace productivity (presenteeism), unemployment, premature mortality, and caregiving costs. Unemployment is the largest contributor to indirect costs ($1.14 billion), followed by costs of absenteeism and presenteeism ($285 million). Caregiving costs for children with IBD are estimated to be nearly $58 million. Canadians with IBD also pay $536 million every year for care that is not covered by universal or supplemental private health insurance; this includes allied healthcare (e.g., care provided by psychologists), medication, and other supportive therapy. Combined, the indirect and out-of-pocket costs of IBD in Canada are estimated at more than $2 billion CAD in 2023. This is substantially higher than the estimate of $1.29 billion in Crohn's and Colitis Canada's 2018 Impact of IBD report with differences attributable to a combination of rising prevalence, inflation, and the addition of presenteeism and caregiving costs to the total indirect costs.

Kuenzig ME ，Im JHB ，Coward S ，Windsor JW ，Kaplan GG ，Murthy SK ，Benchimol EI ，Bernstein CN ，Bitton A ，Jones JL ，Lee K ，Peña-Sánchez JN ，Rohatinsky N ，Ghandeharian S ，Jones May T ，Tabatabavakili S ，Jogendran R ，Weinstein J ，Khan R ，Hazan E ，Browne M ，Davis T ，Goddard Q ，Gorospe J ，Latos K ，Mason K ，Kerr J ，Balche N ，Sklar A ，Targownik LE ... -  《-》

Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.

Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn's and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn's and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn's and Colitis Canada's webinar-based knowledge translation platform.

Ellen Kuenzig M ，Windsor JW ，Barrett L ，Bernstein CN ，Bitton A ，Carroll MW ，Chauhan U ，Coward S ，Fowler S ，Ghia JE ，Geist R ，Gibson DL ，Graff LA ，Griffiths AM ，Guoxian Huang J ，Jones JL ，Khanna R ，Lakatos PL ，Lee K ，Mack DR ，Marshall JK ，Mukhtar MS ，Murthy SK ，Nguyen GC ，Panaccione R ，Seow CH ，Singh H ，Tandon P ，Targownik LE ，Zelinsky S ，Benchimol EI ，Kaplan GG ... -  《-》